Centiva Capital LP Reduces Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Centiva Capital LP lessened its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 53.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,431 shares of the medical instruments supplier’s stock after selling 72,545 shares during the quarter. Centiva Capital LP owned about 0.09% of OraSure Technologies worth $275,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in OSUR. AXA S.A. grew its stake in shares of OraSure Technologies by 2.5% during the second quarter. AXA S.A. now owns 161,614 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 3,997 shares in the last quarter. SG Americas Securities LLC grew its stake in OraSure Technologies by 46.4% during the 2nd quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier’s stock valued at $73,000 after purchasing an additional 5,431 shares in the last quarter. Koss Olinger Consulting LLC increased its holdings in OraSure Technologies by 9.4% during the 3rd quarter. Koss Olinger Consulting LLC now owns 83,977 shares of the medical instruments supplier’s stock worth $359,000 after purchasing an additional 7,247 shares during the last quarter. Atom Investors LP acquired a new position in shares of OraSure Technologies in the 3rd quarter valued at approximately $49,000. Finally, SkyView Investment Advisors LLC boosted its stake in shares of OraSure Technologies by 100.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 12,000 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday.

OraSure Technologies Stock Up 7.9 %

Shares of OraSure Technologies stock opened at $4.11 on Thursday. The business has a 50-day moving average price of $4.03 and a 200 day moving average price of $4.24. OraSure Technologies, Inc. has a fifty-two week low of $3.72 and a fifty-two week high of $8.45. The firm has a market cap of $306.58 million, a P/E ratio of 27.40 and a beta of 0.03.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The business had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. During the same period in the prior year, the company posted $0.27 EPS. The business’s revenue was down 55.2% compared to the same quarter last year. As a group, equities research analysts anticipate that OraSure Technologies, Inc. will post -0.07 earnings per share for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.